Discovery of candidate biomarkers

John E. Wiktorowicz, Kizhake V. Soman

    Research output: Chapter in Book/Report/Conference proceedingChapter

    3 Citations (Scopus)

    Abstract

    Properly performed, biomarker discovery can lead to effective candidates that can ultimately serve as predictors of disease, medical condition, define therapeutic parameters, and many other applications in medicine. Preferably, biomarkers comprise a panel of indicators, e.g. proteins and/or peptides that can be predictive or diagnostic of the medical condition of interest. Emphasis here is placed on “panel,” as single candidates are rarely sufficient to provide the necessary sensitivity and specificity. To develop an effective panel that survives the development process described in Chap. 19, proper experimental design and attention to important statistical parameters are critical to ensure success. Errors in discovery can lead to an inefficient use of expensive resources, as these may not be uncovered until the latter stages in biomarker development. Hence, accuracy, precision, and an estimate of the power of the proposed analyses are critical in the discovery of the panel of candidate biomarkers by proteomic methods, as is the selection of statistical approaches to refine and appropriately reduce the dataset for subsequent confirmatory assays.

    Original languageEnglish (US)
    Title of host publicationAdvances in Experimental Medicine and Biology
    PublisherSpringer New York LLC
    Pages443-462
    Number of pages20
    Volume919
    DOIs
    StatePublished - 2016

    Publication series

    NameAdvances in Experimental Medicine and Biology
    Volume919
    ISSN (Print)00652598
    ISSN (Electronic)22148019

    Fingerprint

    Biomarkers
    Proteomics
    Design of experiments
    Medicine
    Assays
    Research Design
    Sensitivity and Specificity
    Peptides
    Proteins
    Therapeutics

    Keywords

    • Antibody depletion
    • Biomarker discovery
    • Plasma
    • Protein pool
    • Serum

    ASJC Scopus subject areas

    • Medicine(all)
    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Wiktorowicz, J. E., & Soman, K. V. (2016). Discovery of candidate biomarkers. In Advances in Experimental Medicine and Biology (Vol. 919, pp. 443-462). (Advances in Experimental Medicine and Biology; Vol. 919). Springer New York LLC. https://doi.org/10.1007/978-3-319-41448-5_21

    Discovery of candidate biomarkers. / Wiktorowicz, John E.; Soman, Kizhake V.

    Advances in Experimental Medicine and Biology. Vol. 919 Springer New York LLC, 2016. p. 443-462 (Advances in Experimental Medicine and Biology; Vol. 919).

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Wiktorowicz, JE & Soman, KV 2016, Discovery of candidate biomarkers. in Advances in Experimental Medicine and Biology. vol. 919, Advances in Experimental Medicine and Biology, vol. 919, Springer New York LLC, pp. 443-462. https://doi.org/10.1007/978-3-319-41448-5_21
    Wiktorowicz JE, Soman KV. Discovery of candidate biomarkers. In Advances in Experimental Medicine and Biology. Vol. 919. Springer New York LLC. 2016. p. 443-462. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-41448-5_21
    Wiktorowicz, John E. ; Soman, Kizhake V. / Discovery of candidate biomarkers. Advances in Experimental Medicine and Biology. Vol. 919 Springer New York LLC, 2016. pp. 443-462 (Advances in Experimental Medicine and Biology).
    @inbook{3d5a00d7f876450785338287413970fc,
    title = "Discovery of candidate biomarkers",
    abstract = "Properly performed, biomarker discovery can lead to effective candidates that can ultimately serve as predictors of disease, medical condition, define therapeutic parameters, and many other applications in medicine. Preferably, biomarkers comprise a panel of indicators, e.g. proteins and/or peptides that can be predictive or diagnostic of the medical condition of interest. Emphasis here is placed on “panel,” as single candidates are rarely sufficient to provide the necessary sensitivity and specificity. To develop an effective panel that survives the development process described in Chap. 19, proper experimental design and attention to important statistical parameters are critical to ensure success. Errors in discovery can lead to an inefficient use of expensive resources, as these may not be uncovered until the latter stages in biomarker development. Hence, accuracy, precision, and an estimate of the power of the proposed analyses are critical in the discovery of the panel of candidate biomarkers by proteomic methods, as is the selection of statistical approaches to refine and appropriately reduce the dataset for subsequent confirmatory assays.",
    keywords = "Antibody depletion, Biomarker discovery, Plasma, Protein pool, Serum",
    author = "Wiktorowicz, {John E.} and Soman, {Kizhake V.}",
    year = "2016",
    doi = "10.1007/978-3-319-41448-5_21",
    language = "English (US)",
    volume = "919",
    series = "Advances in Experimental Medicine and Biology",
    publisher = "Springer New York LLC",
    pages = "443--462",
    booktitle = "Advances in Experimental Medicine and Biology",

    }

    TY - CHAP

    T1 - Discovery of candidate biomarkers

    AU - Wiktorowicz, John E.

    AU - Soman, Kizhake V.

    PY - 2016

    Y1 - 2016

    N2 - Properly performed, biomarker discovery can lead to effective candidates that can ultimately serve as predictors of disease, medical condition, define therapeutic parameters, and many other applications in medicine. Preferably, biomarkers comprise a panel of indicators, e.g. proteins and/or peptides that can be predictive or diagnostic of the medical condition of interest. Emphasis here is placed on “panel,” as single candidates are rarely sufficient to provide the necessary sensitivity and specificity. To develop an effective panel that survives the development process described in Chap. 19, proper experimental design and attention to important statistical parameters are critical to ensure success. Errors in discovery can lead to an inefficient use of expensive resources, as these may not be uncovered until the latter stages in biomarker development. Hence, accuracy, precision, and an estimate of the power of the proposed analyses are critical in the discovery of the panel of candidate biomarkers by proteomic methods, as is the selection of statistical approaches to refine and appropriately reduce the dataset for subsequent confirmatory assays.

    AB - Properly performed, biomarker discovery can lead to effective candidates that can ultimately serve as predictors of disease, medical condition, define therapeutic parameters, and many other applications in medicine. Preferably, biomarkers comprise a panel of indicators, e.g. proteins and/or peptides that can be predictive or diagnostic of the medical condition of interest. Emphasis here is placed on “panel,” as single candidates are rarely sufficient to provide the necessary sensitivity and specificity. To develop an effective panel that survives the development process described in Chap. 19, proper experimental design and attention to important statistical parameters are critical to ensure success. Errors in discovery can lead to an inefficient use of expensive resources, as these may not be uncovered until the latter stages in biomarker development. Hence, accuracy, precision, and an estimate of the power of the proposed analyses are critical in the discovery of the panel of candidate biomarkers by proteomic methods, as is the selection of statistical approaches to refine and appropriately reduce the dataset for subsequent confirmatory assays.

    KW - Antibody depletion

    KW - Biomarker discovery

    KW - Plasma

    KW - Protein pool

    KW - Serum

    UR - http://www.scopus.com/inward/record.url?scp=85006421887&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85006421887&partnerID=8YFLogxK

    U2 - 10.1007/978-3-319-41448-5_21

    DO - 10.1007/978-3-319-41448-5_21

    M3 - Chapter

    C2 - 27975230

    AN - SCOPUS:85006421887

    VL - 919

    T3 - Advances in Experimental Medicine and Biology

    SP - 443

    EP - 462

    BT - Advances in Experimental Medicine and Biology

    PB - Springer New York LLC

    ER -